Latest News and Press Releases

Company announcement – No. 31 / 2023 Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism US FDA has granted priority review...

Company announcement - No. 28 / 2023 Zealand Pharma Announces Financial Results for the First Half of 2023 Strong progress across R&D pipeline and significant strengthening of the balance...

Press release – No. 8 / 2023 Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism Copenhagen, Denmark, June 30, 2023 – Zealand Pharma A/S...

Press release – No. 2 / 2023 Zealand Pharma to Participate in 22nd Annual Needham Virtual Healthcare Conference Copenhagen, Denmark, April 12, 2023 – Zealand Pharma A/S (Nasdaq...

Press release – No. 5 / 2022 Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting Dasiglucagon significantly...

SAN DIEGO, June 08, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that results from the company’s Phase 1 study of CRN04894, the company’s investigational...

Results Further Support Clinical Proof-of-Concept for CRN04777 by Showing Dose-Dependent Decreases in Fasting and Sulfonylurea-Induced Insulin Secretion Management Hosting Webcast and Conference Call...

CRN04777 Phase 1 Program Progressing to Multiple Ascending Dose Cohorts to Advance Development as a Treatment for Congenital Hyperinsulinisms Demonstrated Dose-dependent Reductions in...

SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...

- Details of New Paltusotine Tablet Formulation to be Unveiled - - Preclinical Evidence Supporting Programs in Congenital Hyperinsulinism and Congenital Adrenal Hyperplasia and Cushing’s Disease...